Date of event
Continuing Education Credits
AASLD COVID-19 Clinical Oversight & Publications Subcommittee
- Patricia Harren, DNP, DCC
Columbia University Medical Center
- David C. Mulligan, MD, FAASLD
- Bilal Hameed, MD
University of California, San Francisco
- Kimberly Ann Brown, MD, FAASLD
Henry Ford Health System
- Jaime Chu, MD
Icahn School of Medicine at Mount Sinai
- Oren K. Fix, MD, MSc, FAASLD
Swedish Medical Center
- Guadalupe Garcia-Tsao, MD, FAASLD
- Ryutaro Hirose, MD
University of California, San Francisco
- Karen Hoyt
Patient Advocate, AASLD’s COVID-19 Task Force
- K. Gautham Reddy, MD, FAASLD
University of Chicago Medical Center
- Elizabeth C. Verna, MD, MS
Columbia University Medical Center
As the COVID-19 pandemic continues to evolve, AASLD is committed to helping our members and the broader community respond to increasing challenges and complexities.
This is the fifth in a series of webinars AASLD is dedicating to ongoing discoveries and discussions about COVID-19 and how it impacts the care of liver patients. Participants will be able to:
- Understand the challenges institutions face in resuming pre-pandemic operations.
- Realize the ways to begin a safe outpatient reentry process for patients with liver disease.
- Describe how transplant centers are carefully planning for reentry.
Watch the Webinar / Download the Presentation
Patricia Harren, DNP, DCC
I have worked in liver disease since 1990 and was named the Clinical Director of the Center for Liver Disease and Transplantation in 2000. In this position, I supervise the operations of a center transplanting more than 120 patients per year. Our staff is comprised of over 100 employees, including 12 physicians, 12 nurse practitioners and 6 physician assistants. Our center sees over 1500 new patients per year with advanced liver disease. In 2005 in addition to my responsibilities in CLDT I was appointed as the Clinical Director for pediatric transplantation and adult abdominal organ transplantation for Columbia University. I hold both pediatric and adult board certifications and my clinical practice spans in and out patient responsibilities.
David C. Mulligan, MD, FAASLD
Dr. David Mulligan is Professor of Surgery and Chief of Transplantation and Immunology at Yale University/Yale New Haven Health System following his arrival in 2013. As a multi-organ transplant surgeon trained at Baylor University in Dallas, TX with a heavy experience in liver transplantation, he joined the faculty at Case Western Reserve University in Cleveland, OH and was quickly recruited by the Mayo Clinic to build a multi-organ transplant program in Arizona. Following the pioneering spirit, he grew a small team was able to assemble a wonderful clinically and academically successful liver, kidney and pancreas transplant program over the course of 15 years. He also had the honor to help establish a successful heart and pediatric liver program at Mayo Clinic and Phoenix Children’s Hospital. He was able to establish a very successful living donor liver transplant program with the highest long-term patient and graft survival in the US.
In the fall of 2013, he joined Yale University and a stimulating faculty to establish a patient-centered, collaborative team environment accompanied by outstanding academic clinical and basic science research. Over the past 7 years, the team is emerging in amazing ways to achieve new heights in outstanding quality and cutting-edge science. They are testing novel strategies in immunosuppression, improved biomechanical organ preservation methods to reduce ischemia/reperfusion injury and promote regeneration as well as work in the field of 3D bioprinting to collaborate in finding ways to grow new organs from stem cell precursors.
Throughout Dr. Mulligan’s career in transplantation, he has remained active in leadership responsibilities for multiple national and international organizations and led major efforts including creating means to reduce the disparity of access to life-saving livers in this country across our current geographic areas. He serves as an At-Large Member of the AASLD Governing Board, Chair of the Business Practice Services Committee of the ASTS, and is President-Elect of UNOS/OPTN. In the recent past, he has served as Chair of the Advisory Council to the Secretary of HHS on Transplantation (ACOT), Councilor of ASTS aswell as Chair of Membership and Standards Committees, and has led numerous committees for UNOS/OPTN such as the Liver and Intestinal Transplant Committee and Membership and Professional Standards Committee. He has generated special clinical recognition in the area of living donor liver transplantation having performed more than 200 cases.
Academically, Dr. Mulligan has authored over 150 papers inpeer-reviewed journals and 9 book chapters. He has been co-PI and sub-I on numerous Federal and Institutional grants. He has been invited to lecture around the world on liver transplantation, living donation, organ allocation, and insights into the future of solid organ transplantation. The team at Yale is also working on ways to develop a healthier, more integrated team and build self-care and resilience in our practice and for our patients across the entire Yale Health System. He feels privileged to work with an amazing team of surgeons, hepatologists, nephrologists, immunologists, and nurses to continue work in this rewarding field and pledge to continue my efforts to lead our community to find better ways to provide the best possible patient care in the safest environments.
Bilal Hameed, MD
Dr. Bilal Hameed is the Associate Professor of Medicine and the Hepatology Clinic Chief at the University of California, San Francisco. He is the section editor for the journal Gastroenterology. He is a board member of the Northern California Society for Clinical Gastroenterology. He has authored more than 30 original articles, reviews and book chapters on NASH and ALF in various prestigious journals. He is the PI for Acute Liver Failure Study Group (ALFSG) and co-investigator on an NIH-funded study on NASH. He is an investigator on several ongoing clinical trials for patients with NASH, PSC and chronic liver diseases. He is recognized nationally and internationally for his work related to Nonalcoholic Steatohepatitis (NASH) and Acute Liver Failure (ALF).
Kimberly A. Brown, MD, FAST, FAASLD, AGAF
Dr. Kimberly A. Brown is the Chief of Gastroenterology and Hepatology at Henry Ford Hospital in Detroit. She joined the Henry Ford Medical Group in 1995 as medical director of the liver transplant program and was appointed Chief of the division of gastroenterology and hepatology in 2003. In addition, she served as the program director for the GI fellowship program from 2003 to 2008.
Dr. Brown received her undergraduate degree from the University of Michigan in 1981. She completed her medical degree at Wayne State University in 1985. Dr. Brown completed both her residency in internal medicine as well as her fellowship in gastroenterology at the University of Michigan in 1992 and was named chief medical resident in 1984-85.
Dr. Brown is a member of the American Gastroenterology Association, the American Association for the Study of Liver Disease, the American College of Gastroenterology, The European Association for the Study of Liver Disease, and the American Society of Transplantation. She served on the Board of Governors of the Henry Ford Medical Group for nine years, the Henry Ford Hospital and System Network Board for three years, and was past co-chair of the Michigan Chapter of the American Liver Foundation. She has served as the treasurer of the Board of the American Society of Transplantation and is involved with several committees for both the society and hospital. She is a past member of the UNOS Liver and Intestines Committee and the Executive Board for the Liver and Intestines Community of Practice for the AST. Dr. Brown is currently serving as secretary to AASLD.
As Chief of Gastroenterology and Hepatology and past medical director of liver transplantation, Dr. Brown sees and manages patients with complex liver disease both before and after liver transplantation. In conjunction with Dr Abouljoud, she worked to develop the leading liver transplant program in the State of Michigan. As fellowship director, she managed a fellowship program of 12 GI/liver fellows and continues to be involved in structuring and monitoring their education and academic success. She has published more than 70 articles, 80 abstracts and eight book chapters/reviews and is a very active clinical investigator in viral hepatitis, advanced liver disease and post liver transplant management. She is also a past award winner of the Castle Connelly National Top Doc Award for Clinical Excellence and Henry Ford Medical Group Fred Whitehouse Award for Clinical Excellence. She is also the Associate Director of the HFH Transplant Institute.